Fulvestrant

Drug Profile

Fulvestrant

Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor Research Institute
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Precocious puberty
  • No development reported Endometrial cancer
  • Discontinued Endometriosis

Most Recent Events

  • 27 Jul 2017 Launched for Breast cancer (First-line therapy, Late-stage disease, Metastatic disease) in Iceland, Liechtenstein, Norway, European Union (IM)
  • 26 Jul 2017 Registered for Breast cancer (First-line therapy, Late-stage disease, Metastatic disease) in European Union, Norway, Iceland, Liechtenstein (IM)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory application for Breast cancer (First-line therapy, Late-stage disease, Metastatic disease) in China in H2-2017 (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top